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Abstract
Background: Various chemotherapy regimens for advanced colorectal cancer have been introduced to clinical
practice in Japan over the past decade. The cost profiles of these regimens, however, remain unclear in Japan. To
explore the detailed costs of different regimens used to treat advanced colorectal cancer during the entire course
of chemotherapy in patients treated in a practical setting, we conducted a so-called “real-world” cost analysis.
Method: A detailed cost analysis was performed retrospectively. Patients with advanced colorectal cancer who had
received chemotherapy in a practical healthcare setting from July 2004 through October 2010 were extracted from
the ordering system database of Showa University Hospital. Direct medical costs of chemotherapy regimens were
calculated from the hospital billing data of the patients. The analysis was conducted from a payer’s perspective.
Results: A total of 30 patients with advanced colorectal cancer were identified. Twenty patients received up to
second-line treatment, and 8 received up to third-line treatment. The regimens identified from among all courses
of treatment in all patients were 13 oxaliplatin-based regimens, 31 irinotecan-based regimens, and 11 regimens
including molecular targeted agents. The average (95 % confidence interval [95 % CI]) monthly cost during the overall
period from the beginning of treatment to the end of treatment was 308,363 (258,792 to 357,933) Japanese yen (JPY).
According to the type of regimen, the average monthly cost was 418,463 (357,413 to 479,513) JPY for oxaliplatin-based
regimens, 215,499 (188,359 to 242,639) JPY for irinotecan-based regimens, and 705,460 (586,733 to 824,187) JPY for
regimens including molecular targeted agents. Anticancer drug costs and hospital fees accounted for 50 to 77 % and
11 to 25 % of the overall costs of chemotherapy, respectively.
Conclusion: The costs of irinotecan-based regimens were lower than those of oxaliplatin-based regimens and
regimens including molecular targeted agents in Japan. Using a lower cost regimen for first-line treatment can
potentially reduce the overall cost of chemotherapy. The main cost drivers were the anticancer drug costs and
hospitalization costs.
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Background
Colorectal cancer is currently one of the most common
cancers worldwide [1]. In Japan the incidence of colo-
rectal cancer was 119,000 in 2010 [2], and there were
48,000 deaths from the disease in 2013 [3]. The disease
is already advanced at the time of diagnosis in 56 % of
patients [2]. Surgery is the treatment of choice for
early-stage colorectal cancer, while most patients with
advanced colorectal cancer receive chemotherapy.
A combination of 5-fluorouracil (5-FU) and leucov-
orin (LV) was the standard regimen for advanced colo-
rectal cancer during the 1980s and 1990s. After the
year 2000, FOLFOX (oxaliplatin plus 5-FU and LV) and
FOLFIRI (irinotecan plus 5-FU and LV) were developed
and modified over the course of several years. These
regimens extended progression-free survival to more
than 8 months [4]. Furthermore, regimens including
molecular targeted agents such as bevacizumab (Bev) or
cetuximab (Cet) have prolonged progression-free survival
to 9 to 11 months [5]. Currently, both FOLFOX and FOL-
FIRI with or without molecular targeted agents are
commonly used to manage advanced colorectal cancer
throughout the world [6–8]. Meanwhile, regimens in-
cluding easy-to-administer oral agents were demanded,
because both FOLFOX and FOLFIRI require continu-
ous infusion of 5-FU for 2 days, which was not conveni-
ent in practice. A regimen combining the oral agent
capecitabine with oxaliplatin (XELOX) was developed
for the treatment of colorectal cancer. Two phase III
trials showed that progression-free survival of patients
who received XELOX is non-inferior to that of patients
who received FOLFOX [9, 10], and XELOX is now used
worldwide. In Japan, a regimen combining oral S-1 (a
combination of tegafur, gimeracil, and oteracil), which
was already widely used to treat gastric cancer, with iri-
notecan (IRIS) was developed for the management of
advanced colorectal cancer [11]. The FIRIS study dem-
onstrated that the progression-free survival of patients
in the IRIS group was non-inferior to that in the FOL-
FIRI group [12], and IRIS is now one treatment option
for this disease.
Despite the usefulness of various regimens for the
treatment of advanced colorectal cancer, the develop-
ment of new combination regimens has also attracted
the attention of payers as well as physicians owing to the
high costs of chemotherapy for colorectal cancer. The
national medical expenditure in Japan reached 39.2 tril-
lion JPY in 2011 [13]. Above all, the growing costs of
cancer treatment are a burden to both the national med-
ical expenditure and the out-of-pocket costs paid by
patients. A number of researchers have reported the re-
sults of economic evaluations of colorectal cancer treat-
ment in Japan [14–16]. All of these evaluations have
provided useful information to decision makers and
practitioners. However, the economic information in all
except one [16] of these reports is insufficient for prac-
tical clinical use owing to the limited setting, such as
clinical trials and controlled studies. In other words,
cost-related data on the costs of chemotherapy in a prac-
tical clinical setting are thought to differ from data de-
rived from planned clinical studies. Furthermore, the
comprehensive economic profile of chemotherapy from
first-line to the end of treatment for colorectal cancer is
unclear in clinical trials. One task force of the Inter-
national Society for Pharmacoeconomics and Outcomes
Research (ISPOR) has reported the advantages of real-
world data [17], and another task force of the ISPOR
has provided a questionnaire to assess the relevance
and credibility of observational studies designed to fill
the gap between clinical trials and actual clinical prac-
tice [18].
We have recently reported the results of a cost-
minimization analysis comparing S-1-based regimens
with 5FU-based regimens for advanced colorectal can-
cer in Japan [19]. In the present study, we focused on
the comprehensive economic profile of chemotherapy
and performed a detailed cost analysis of various regi-
mens used to manage this disease from first-line treat-




We undertook a real-world cost analysis to compare
the detailed costs of different chemotherapy regimens
used for advanced colorectal cancer from first-line
treatment to the end of chemotherapy in a practical set-
ting. The analysis was retrospectively performed from a
payer’s perspective. The costs of healthcare-related ser-
vices were calculated from the payer side using billing
data obtained from Showa University Hospital. Showa
University Hospital is a general hospital located in
Tokyo that has approximately 800 beds as well as out-
patient clinics. The fees are the same for all payers and
virtually all providers in Japan and are set by the gov-
ernment in the national fee schedule [20]. The study
was approved by the Medical Ethics Committee of
Showa University Hospital (approved number: 981).
We retrospectively collected clinical and claim data on
patients with advanced colorectal cancer in this observa-
tional study. Because most of the patients died before
this study began, it was difficult to obtain written con-
sent from the patients. We analyzed the data after re-
moving all personal information to protect privacy. This
approach was in accordance with the Japanese Ethical
Guidelines for Epidemiological Studies [21]; moreover,
before the study began the Internal Review Board deter-
mined that consent is not required.
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Patients and chemotherapy regimens
The study group comprised patients who were given a
diagnosis of advanced colorectal cancer and received
chemotherapy until the end of the final line of chemo-
therapy in the Department of Surgery, Showa University
Hospital during the period from July 2004 through October
2010. We extracted data on all lines of chemotherapy
given to all patients and classified the regimens into
the following three groups: oxaliplatin-based regimens,
irinotecan-based regimens, and regimens including mo-
lecular targeted agents.
Resource utilization data and costs
Resource utilization data on each chemotherapy regimen
was extracted from Showa University Hospital billing
data. The following costs were calculated on a monthly
basis and were summed up on the basis of the Japanese
National Health Insurance fee-for-service system (reim-
bursement price) in 2010: costs related to outpatient
visits (physician consultations and outpatient visits);
costs for hospitalization (basic bed charges, medical ex-
aminations, nursing care, and basic treatments during
hospitalization); costs for operations and procedures (in-
cluding transfusions); costs for laboratory tests and diag-
nostic imaging tests (radiography, computed tomography,
magnetic resonance imaging, ultrasonography); costs for
drugs and administration (anticancer drugs, antiemetics,
and other drugs, including preparation and administration
costs). Costs unrelated to cancer, such as costs required
for the management of hypertension and hyperlipid-
emia, and operation fees, such as those required for the
creation of an artificial anus, were not considered. Extra
bed fees and meal fees were collected from billing data
as a reference.
In this study, we collected data on regimens regardless
of the treatment line, and then found that the duration
of each regimen was influenced by the treatment line.
The duration of the first line of treatment was longer
than those of second and third lines. Therefore, the costs
of each chemotherapy regimen were compared on a
monthly basis to avoid the effects of the different dura-
tions of treatment.
Time horizon and discounts
The monthly average costs of all chemotherapy
regimens from first-line to the end of the final line
of treatment were analyzed over the course of
time. Treatments costs during the period of terminal
care were not considered because it was difficult to col-
lect relevant data during that period, and the costs var-
ied depending on the status of individual patients
during terminal care, regardless of the regimens used
previously. Trends in the breakdown of costs were also
analyzed in detail. Costs for more than 1 year were dis-
counted by 3 %.
Sensitivity analysis
The uncertainty of the results was explored by sensitivity
analyses of uncertain factors. Several qualitative, one-way
sensitivity analyses were conducted to explore the impact
of alternative parametric assumptions on the results.
Results
Characteristics of patients and chemotherapy regimens
The characteristics of the 30 patients identified from the
patient database of Showa University Hospital are shown
in Table 1. The average age was 62.8 years. The major
sites of colorectal cancer were the cecum in 4 patients,
the ascending colon in 3, the transverse colon in 2, the
descending colon in 1, the sigmoid colon in 7, and the
rectum in 13. The rate of hospitalization was 23 %. The
average duration of the entire course of chemotherapy
was 13.5 months. Among the 30 patients, 20 received up
to second-line chemotherapy, and 8 received up to
third-line chemotherapy. The following different regimens
were identified from among all courses of treatment in all
patients: 13 oxaliplatin-based regimens (12 FOLFOX regi-
mens and 1 XELOX regimen); 31 irinotecan-based regi-
mens (27 IRIS regimens and 4 FOLFIRI regimens); 11
regimens including molecular targeted agents (6 FOL-
FOX + Bev regimens, 4 FOLFIRI + Bev or Cet regimens
and 1 XELOX + Bev regimen); and 3 other regimens (2
Bev regimens and 1 Cet regimen). The schedules of
each regimen are presented in Additional file 1.
The numbers of regimens and the durations of each
treatment line are shown in Table 2. Two oxaliplatin-based
regimens (2 FOLFOX regimens), 27 irinotecan-based regi-
mens (27 IRIS regimens), and 1 regimen including molecu-
lar targeted agents (1 FOLFIRI + Bev regimen) were given
as first-line treatment. Eleven oxaliplatin-based regimens
(10 FOLFOX regimens, 1 XELOX regimen), 8 regimens in-
cluding molecular targeted agents (6 FOLFOX+Bev regi-
mens, 1 FOLFIRI + Cet regimen, 1 XELOX+Bev regimen)
and 1 Bev regimen were given as second-line treatment.
Four irinotecan-based regimens (4 FOLFIRI regimens), 2
regimens including molecular targeted agents (1 FOL-
FIRI + Bev regimen, 1 FOLFIRI + Cet regimen), 1 Bev
regimen and 1 Cet regimen were given as third-line
treatment. The average duration of each line was
9.0 months for first-line, 3.9 months for second-line,
and 3.8 months for third-line. The average duration of
chemotherapy according to the type of regimen was
3.9 months for oxaliplatin-based regimens, 8.8 months
for irinotecan-based regimens, and 4.3 months for regi-
mens including molecular targeted agents.
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Costs
Total costs for the entire course of chemotherapy and costs
according to regimen group
The monthly total costs are shown in Table 3 and Fig. 1,
and the time courses of the total costs of each regimen
group are shown in Fig. 2.
The average (95 % CI, minimum, 75th percentile, me-
dian, 75th percentile, maximum) monthly cost during
the overall period from the beginning of treatment to
the end of treatment was 308,363 (258,792 to 357,933,
152,345, 208,653, 270,328, 340,179, 637,299) JPY. The
monthly costs varied over time. The first cost peak
occurred in the first month, and the cost gradually in-
creased from the fifth to the twelfth month. During this
period, some patients started to receive expensive second-
line treatments. The second cost peak occurred in the
twelfth month and overlapped with the peak in the first
month of third-line treatment. The average (95 % CI,
minimum, 75th percentile, median, 75th percentile, max-
imum) monthly costs were 256,149 (207,992 to 304,307,
149,816, 186,293, 208,555, 261,922, 637,299) JPY for first-
line treatment, 518,897 (431,290 to 606,504, 280,977,
348,454, 431,758, 650,541, 925,339) JPY for second-line,
and 416,251 (188,316 to 644,185, 141,582, 162,033,
297,117, 600,389, 1,056,666) JPY for third-line.
The average (95 % CI, minimum, 75th percentile, me-
dian, 75th percentile, maximum) monthly costs of
oxaliplatin-based regimens, irinotecan-based regimens,
and regimens including molecular targeted agents were
respectively 418,463 (357,413 to 479,513, 280,977, 339,667,
399,767, 444,406, 635,115) JPY, 215,499 (188,359 to
242,639, 141,867, 171,990, 207,516, 223,415, 567,549) JPY,
and 705,460 (586,733 to 824,187, 411,384, 597,586, 710,434,
822,972, 1,056,666) JPY. The costs of irinotecan-based regi-
mens were lower than those of oxaliplatin-based regimens
and regimens including molecular targeted agents.
Cost-component analysis
The monthly component costs of each regimen group
up to the twelfth month of treatment are shown in
Table 4.
The cost drivers were anticancer drugs and hospi-
talization. The costs of anticancer drugs were 228,539
JPY (proportion of total: 58 %) for oxaliplatin-based
regimens, 96,853 JPY (50 %) for irinotecan-based regi-
mens, and 535,214 JPY (77 %) for regimens including
molecular targeted agents. The costs were lower for
irinotecan-based regimens than for oxaliplatin-based
regimens and regimens including molecular targeted
agents. The hospital fees were 89,935 JPY (21 %) for
oxaliplatin-based regimens, 53,584 JPY (25 %) for
irinotecan-based regimens, and 77,752 JPY (11 %) for
regimens including molecular targeted agents. Next to
the costs of anticancer drugs, hospital fees were second
highest costs for all regimen groups.
The costs of other components were as follows. The ad-
ministration costs for drug administration were 19,882
JPY for oxaliplatin-based regimens and 16,133 JPY for reg-
imens including molecular targeted agents, which were
higher than the 12,543 JPY for irinotecan-based regimens.
Table 1 Patient characteristics
















Rate of hospitalization 23 %












Regimens including molecular targeted agents 11
FOLFOX + Bev 6
FOLFIRI + Bev or Cet 4
XELOX + Bev 1
Others 3
Overall treatment period = from the beginning of treatment to the end of the
final line of chemotherapy (All of the patients had died or were in terminal
care phase as of the study endpoint)
The numbers of each regimen were counted from among all courses of
treatment in all patients
FOLFOX oxaliplatin plus 5-fluorouracil and leucovorin; FOLFIRI irinotecan plus
5-fluorouracil and leucovorin; XELOX oxaliplatin plus capecitabine; IRIS irinotecan
plus S-1 (tegafur, gimeracil and oteracil combination); Bev bevacizumab; Cet
cetuximab; Others 2 Bev and 1 Cet
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The diagnostic imaging cost for irinotecan-based regimens
was 24,039 JPY, which was higher than the costs in the
other regimen groups. The operation fees were 37,353 JPY
for oxaliplatin-based regimens and 38,222 JPY for regi-
mens including molecular targeted agents, which were
higher than the operation fees for irinotecan-based
regimens.
Sensitivity analysis
The results of sensitivity analysis are shown in Table 5.
As mentioned above, the treatment line differed among
the regimens in this study. There was some bias, which
most likely depended on the treatment line. Regimens
used as first-line during the first month of treatment
tended to be administered in the hospital, and the
hospital fee accounted for a large proportion of total
costs and might have influenced the results. We there-
fore initially performed a simple sensitivity analysis to
examine the hospital fee. Two scenarios were consid-
ered: 3 days’ hospitalization and an outpatient setting.
As a result, the orders of the total costs among the
regimen groups given on an inpatient basis and an out-
patient basis were basically same as the order of the total
costs in the regimen groups for the base-case. As for
oxaliplatin-based regimens and regimens including mo-
lecular targeted agents, the base-case costs were slightly
higher than those of a 3-day hospitalization setting be-
cause the period of hospitalization was longer than 3 days
for the base-case. The costs for diagnostic imaging tests
were higher for irinotecan-based regimens than for the
Table 2 Numbers of regimens used in each treatment line and durations of each treatment line
First-line Second-line Third-line Average durations of treatment (month)
Total 30 20 8 6.5
Oxaliplatin-based regimens 2 11 3.9
FOLFOX 2 10 3.8
XELOX 1 5.0
Irinotecan-based regimens 27 4 8.8
IRIS 27 9.3
FOLFIRI 4 5.8
Regimens including molecular targeted agents 1 8 2 4.3
FOLFOX + Bev 6 5.0
FOLFIRI + Bev or Cet 1 1 2 4.0
XELOX + Bev 1 1.0
Others 1 2 1.3
Average durations of treatment (month) 9.0 3.9 3.8
Table 3 Average monthly total costs (JPY)
Total costs (mean) 95 % CI Minimum 25th percentile Median 75th percentile Maximum
Overall treatment period
(n = 30)
308,363 (258,792–357,933) 152,345 208,653 270,328 340,179 637,299
First-line treatment
(n = 30)
256,149 (207,992–304,307) 149,816 186,293 208,555 261,922 637,299
Second-line treatment
(n = 20)
518,897 (431,290–606,504) 280,977 348,454 431,758 650,541 925,339
Third-line treatment
(n = 8)
416,251 (188,316–644,185) 141,582 162,033 297,117 600,389 1,056,666
Oxaliplatin-based regimens
(n = 13)
418,463 (357,413–479,513) 280,977 339,667 399,767 444,406 635,115
Irinotecan-based regimens
(n = 31)
215,499 (188,359–242,639) 141,867 171,990 207,516 223,415 567,549
Regimens including molecular targeted
agents (n = 11)
705,460 (586,733–824,187) 411,384 597,586 710,434 822,972 1,056,666
Costs during the overall treatment period were calculated from the beginning of treatment to the end of treatment and were discounted by 3 % after the
twelfth month
The costs of first-line, second-line, and third-line treatments were calculated until the end of each treatment and were discounted by 3 % after the twelfth month
The costs of each regimen group were calculated until the twelfth month and were not discounted
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other regimen groups because IRIS, which was the most
commonly used irinotecan-based regimen, was mainly
used for first-line treatment, during which diagnostic im-
aging tests were frequently performed to assess disease
progression. Therefore, we performed a simple sensitivity
analysis of the costs for diagnostic imaging tests. The re-
sults demonstrated that the cost of diagnostic imaging
tests did not have an impact on the total costs. In addition,
because the use of generic anticancer drugs may have in-
fluenced the results, we performed a simple sensitivity
analysis comparing the use of generic leucovorin with that
of brand leucovorin. The results did not change.
Discussion
Current clinical guidelines for colorectal cancer [6–8], rec-
ommend FOLFOX or FOLFIRI with or without molecular
targeted agent such as Bev or Cet as first-line treatment.
In the present study, however, the main regimen used for
first-line treatment was the oral S-1-based IRIS regimen.





















Fig. 1 Monthly total costs from the beginning of treatment to the end of treatment. The costs of each line and costs from the beginning of treatment





































Fig. 2 Total costs of each regimen up to the sixth month (mean + 95 % CI)
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cancer in 2003 under Japanese National Health Insurance
before the present study began, and the FIRIS study com-
paring IRIS with FOLFIRI started in 2006 [12]. Therefore,
physicians used the more convenient oral IRIS regimen as
first-line chemotherapy during this study, because they ex-
pected IRIS to be as effective as FOLFIRI, one of the
standard regimens used to treat advanced colorectal can-
cer. On the other hand, molecular targeted agents and
XELOX were virtually not used as first-line treatment dur-
ing this study, because these treatments were approved for
reimbursement under Japanese National Health Insurance
in 2007 and 2009, respectively, which was during the latter
part of this study.
In the present study, the average duration of the en-
tire course of chemotherapy was longer than 1 year,
and the average monthly total cost during the entire
period was 308,363 JPY, which nearly equals the average
wage in Japan [22]. The burden to health insurance and
individuals was thus substantial. The duration of first-line
treatment was 9.0 months, which was longer than the dur-
ation of second and subsequent lines of chemotherapy.
Therefore, the cost of the entire course of chemotherapy
Table 4 Average monthly component costs of each regimen group up to the twelfth month (JPY)
Oxaliplatin-based regimens Irinotecan-based regimens Regimens including molecular
targeted agents
(n = 13) (n = 31) (n = 11)
mean (range) mean (range) mean (range)
Total 418,463 (280,977–635,115) 215,499 (141,867–567,549) 705,460 (411,384–1,056,666)
Outpatient visits 6,051 (500–11,000) 6,329 (3,540–11,000) 5,375 (0–10,488)
Hospitalization 89,935 (14,022–209,077) 53,584 (0–375,985) 77,752 (0–192,950)
Operations and Procedures 37,353 (0–178,780) 455 (0–9,860) 38,222 (0–178,273)
Tests
Laboratory tests 15,289 (4,991–38,970) 11,757 (5,548–41,200) 12,448 (5,833–24,173)
Diagnostic imaging tests 8,512 (0–29,140) 24,039 (1,493–56,330) 8,958 (0–23,118)
Drugs and Administration
Anticancer drugs 228,539 (136,433–364,332) 96,853 (58,335–138,086) 535,214 (177,458–988,262)
Antiemetics 8,688 (6,051–19,636) 9,232 (5,857–12,557) 6,746 (365–11,972)
Other drugs 3,707 (0–19,128) 708 (0–4,347) 4,546 (0–32,316)
Administration 19,882 (2,200–44,160) 12,543 (950–42,930) 16,133 (950–43,610)
Others 508 (0–6,600) 0 67(0–733)
Proportion of hospitalization 21 % 25 % 11 %
Proportion of anticancer drugs 58 % 50 % 77 %
Meal fees 8,677 4,001 4,639
Extra bed fees 67,290 13,364 10,350
Outpatient visits = physician consultations and outpatient visits; Hospitalization = basic bed charges, medical examinations, nursing care, and basic treatments
during hospitalization; Operations = including transfusion; Diagnostic imaging tests = X-ray, CT, MRI, ultrasound; Administration = preparation and management;
Range =minimum to maximum
Table 5 Sensitivity analysis (average monthly total costs: JPY)
Oxaliplatin-based regimens Irinotecan-based regimens Regimens including molecular targeted agents
(n = 13) (n = 31) (n = 11)
Base-case 418,463 215,499 705,460
Hospitalization 390,487 223,597 690,343
Outpatient 327,177 160,287 627,033
Imaging Max 433,991 215,499 720,541
Imaging Min 418,463 199,972 705,013
Brand drug 418,463 215,888 707,715
Generic drug 404,097 214,046 694,883
Hospitalization = in the scenario of 3 days’ hospitalization; Outpatient = in the scenario of outpatient visit; Imaging Max = in the scenario of maximum utilization of
diagnostic imaging tests; Imaging Min = in the scenario of minimum utilization of diagnostic imaging tests; Brand drug = in the scenario of using brand leucovorin;
Generic drug = in the scenario of using generic leucovorin
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seemed to depend primarily on the regimen used for first-
line treatment. In this study, inexpensive IRIS was used
for first-line treatment, which contributed to a lower over-
all cost for chemotherapy.
The costs of oxaliplatin-based regimens such as FOLFOX
were higher than those of irinotecan-based regimens
such as IRIS and FOLFIRI. Regimens including molecu-
lar targeted agents such as Bev and Cet were the most
expensive. Many economic evaluations of colorectal
cancer chemotherapy have been performed in the world
(Table 6). Miyazaki et al., Shiroiwa et al., and Ajima
et al. have reported on the costs of chemotherapy for
advanced colorectal cancer in Japan [14–16]. All of
these studies showed that the cost of FOLFOX is higher
than that of FOLFIRI, consistent with the results of our
study. In the United States, several economic evaluations
of the FOLFOX and FOLFIRI regimens have also reported
that FOLFOX is more expensive than FOLFIRI [23, 24].
In the United Kingdom, however, the costs of FOLFOX
and FOLFIRI are about the same [25, 26]. These differ-
ences seem to be attributed to the different drug prices in
each country. As for molecular targeted agents, several
economic evaluations of Bev have been reported by
Shiroiwa et al., Tappenden et al., and Lee et al. [15, 27, 28].
These studies showed that the cost-effectiveness of Bev is
low. In the United Kingdom, the National Institute for
Health and Care Excellence (NICE) did not recommend
molecular targeted agents as first-line treatment for ad-
vanced colorectal cancer [29].
Hospital fees were thought to be one of the cost drivers.
However, the results of sensitivity analysis showed that the
hospital fees did not influence the total costs. The base-
case costs of oxaliplatin-based regimens and regimens in-
cluding molecular targeted agents were higher than the
cost of the scenario assuming 3 days of hospitalization.
The management of adverse effects was apparently more
difficult for oxaliplatin-based regimens and regimens in-
cluding molecular targeted agents than for other regimens
and thus required a longer hospitalization period.
The cost characteristics of other components were as
follows. The costs associated with drug administration
were higher for oxaliplatin-based regimens (FOLFOX,
etc.) than for irinotecan-based regimens (IRIS, etc.)
because IRIS regimens did not require continuous infu-
sion of 5-FU. The diagnostic imaging costs for
irinotecan-based regimens, used mainly as first-line
treatment, were higher than those for other regimens
because diagnostic imaging was frequently performed
Table 6 Costs of chemotherapy for advanced colorectal cancer in the world (USD, monthly)
Oxaliplatin-based regimens Irinotecan-based regimens Regimens including molecular
targeted agents
Japan (Present study) FOLFOX: 4,141 IRIS: 2,217 FOLFOX + Bev: 7,353
FOLFIRI (2nd line): 1,574 FOLFIRI + Bev or Cet: 6,777
Japan (Miyazaki14) FOLFOX: 4,151 FOLFIRI: 2,398
Japan (Shiroiwa15) FOLFOX: 4,554 FOLFIRI (2nd line): 2,376 FOLFOX + Bev: 7,722
XELOX: 3,564 IFL + Bev: 4,950
XELOX + Bev: 6,831
Japan (Ajima16) FOLFOX: 5,352 FOLFIRI: 3,743
US (Mullins23) FOLFOX: 60,179 (per patient) FOLFIRI: 44,087 (per patient)
US (Tumeh24) FOLFOX: 29,865 (per patient) FOLFIRI: 24,551 (per patient)
US (Chu30) FOLFOX: 14,300
XELOX: 11,473
UK (NICE:HTA200125) FOLFOX: 5,718 FOLFIRI: 5,975
UK (NICE:HTA200826) FOLFOX: 22,734 (per patient) FOLFIRI: 23,017 (per patient)
UK (Tappenden27) IFL: 40,998 (per patient) IFL + Bev: 74,379 (per patient)
France (Perrocheau32) FOLFOX: 23,597 (per patient)
XELOX: 17,695 (per patient)
Koria (Lee28) FOLFIRI: 1,597 Bev: 5,150
UK (Ward31) 5-FU/LV (Mayo): 2,065
Capecitabine: 1,225
UFT/LV: 1,944
IFL irinotecan plus fluorouracil and leucovorin; 5-FU 5-fluorouracil; LV leucovorin; UFT tegafur and uracil combination
Rate: 1 USD (US Dollar) = 101 JPY, 0.58 GBP (British Pound), 0.73 EUR (Euro) (2014/7/9)
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during first-line treatment. Operation fees for place-
ment of a central venous access port for continuous
infusion of 5-FU were high for oxaliplatin-based regi-
mens, because most FOLFOX regimens were used be-
fore FOLFIRI in this study. The costs of antiemetics did
not differ among the regimens.
As reference information, we also collected data on
the extra bed fee paid by patients, which was not in-
cluded in total costs in this study. The price depended
on the type of room, irrespective of the type of regimen.
Such out-of-pocket costs paid by the patient, however,
were a great burden in a practical setting. We need to
consider such out-of-pocket costs from a societal per-
spective in future studies.
Our analysis had several important limitations. First, a
small sample of claim data was collected from a single in-
stitution in this study. It seems to be difficult to generalize
the results of this study. However, standard dosages and
schedules of the regimens in Showa University Hospital
were used. In addition, by grouping the regimens to
compensate for the small numbers of patients who re-
ceived each regimen, we could obtain convincing results
to some extent. Second, the treatment line differed among
the regimens. However, we did not attempt to balance the
background characteristics of the patients according to
each regimen, because treatment dosages and schedules
did not differ between the lines. With regard to this point,
the durations and total costs of each regimen group varied
according to the treatment line. Therefore, we compared
the regimen groups on a monthly basis to eliminate po-
tential effects related to differences in the duration of each
treatment. Ideally, however, we have to directly compare
total costs in a clinical trial. Third, we calculated only dir-
ect costs because our analysis was performed from a
payer’s perspective.
As mentioned above, the most widely used regimen in
this study was oral S-1-based IRIS. Several economic eval-
uations of regimens including oral preparations such as
capecitabine and tegafur-uracil have shown that such regi-
mens are more cost effective than regimens comprising
only injectable preparations [15, 30–32]. In our former
study analyzing treatment costs for gastric cancer [33], S-1
regimens were also less expensive and more convenient
than injectable regimens. Furthermore, in our other
study of colorectal cancer in an outpatient setting [19],
S-1-based regimens were cost saving as compared with
5-FU-based regimens. This result was derived from the
analysis including time costs of administration of anti-
cancer drugs. Therefore, our findings suggest that further
cost-effectiveness analyses comparing the IRIS regimen
with other regimens, taking into account societal costs,
time-related costs, and quality of life, are warranted. We
hope that our results will help decision makers obtain a
more comprehensive view of costs and thereby narrow the
gap between clinical trials and actual clinical practice and
will help clinicians select regimens for individual patients.
Conclusions
The cost of the entire course of chemotherapy for ad-
vanced colorectal cancer was considerably expensive in
Japan. The costs of irinotecan-based regimens such as
IRIS and FOLFIRI were lower than those of oxaliplatin-
based regimens, such as FOLFOX, and regimens including
molecular targeted agents, such as FOLFOX + Bev and
FOLFIRI + Bev or Cet. Using lower cost regimens such as
IRIS as first-line chemotherapy can lead to a reduction in
overall costs for the entire course of chemotherapy, be-
cause the duration of first-line treatment was longer than
the duration of second and subsequent lines of chemo-
therapy. The main cost drivers of treatment for advanced
colorectal cancer were anticancer drug costs and hospital
expenses.
Additional file
Additional file 1: Schedule of each regimen. (DOCX 15 kb)
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